Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 6/20 | 0.68 |
| ▸ | MEP1A | Q16819 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | MMP13 | P45452 | 9/20 | 0.60 |
| ▸ | MMP1 | P03956 | 8/20 | 0.60 |
| ▸ | MMP8 | P22894 | 8/20 | 0.60 |
| ▸ | MMP2 | P08253 | 8/20 | 0.60 |
| ▸ | MMP9 | P14780 | 8/20 | 0.60 |
| ▸ | MMP7 | P09237 | 1/20 | 0.59 |
| ▸ | MMP12 | P39900 | 1/20 | 0.59 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.59 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MMP14 | P50281 | 2/20 | 0.58 |
| ▸ | MMP3 | P08254 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7338644 | 0.87 | MEP1B (0.81) | MEP1BMEP1AALDH1A1MMP13MMP1 | |
| SCHEMBL5295487 | 0.84 | TAS2R14 (0.64) | ALDH1A1KMT2AMEN1MAPTTAS2R14 | |
| SCHEMBL13899083 | 0.84 | MMP2 (0.67) | MEP1BMEP1AMMP13MMP1MMP8 | |
| SCHEMBL7918690 | 0.83 | CA1 (0.60) | MEP1BMEP1AALDH1A1KMT2AMEN1 | |
| SCHEMBL26769801 | 0.82 | MEP1B (0.65) | MEP1BALDH1A1KMT2AMEN1MMP13 | |
| SCHEMBL4540959 | 0.81 | MEN1 (0.64) | ALDH1A1KMT2AMEN1MAPTTAS2R14 | |
| SCHEMBL7686664 | 0.81 | MMP2 (0.57) | MEP1BMEP1AALDH1A1MMP13MMP1 | |
| SCHEMBL7351771 | 0.81 | MMP3 (0.85) | MEP1BMMP13MMP1MMP8MMP2 | |
| SCHEMBL7350511 | 0.80 | MEP1B (0.78) | MEP1BMEP1AALDH1A1MMP13MMP1 | |
| SCHEMBL5899440 | 0.80 | TAS2R14 (0.63) | MEP1BMEP1AALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679220-A | Histone deacetylase inhibitor | METHYLGENE INC | 2010-03-24 | — | — | CN | claimed |
| EP-2139850-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2010-01-06 | — | — | EP | claimed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | claimed |
| WO-2008122115-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-10-16 | — | — | WO | claimed |
| EP-2139850-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2018-09-12 | — | — | EP | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| CN-101679220-A | Histone deacetylase inhibitor | METHYLGENE INC | 2010-03-24 | — | — | CN | disclosed |
| US-7659293-B2 | α-Amino-N-hydroxy-acetamide derivatives | NOVARTIS AG (CH) | 2010-02-09 | — | — | US | disclosed |
| EP-2139850-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2010-01-06 | — | — | EP | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| EP-0766672-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 2000-10-04 | — | — | EP | disclosed |
| EP-0606046-B1 | Arylsulfonamido-substituted hydroxamic acids | CIBA GEIGY AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996040101-A1 | CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5455258-A | Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0606046-A1 | Arylsulfonamido-substituted hydroxamic acids | CIBA-GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | MEP1B 1705/4885MEP1A 1954/4885ALDH1A1 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.